Isterian Biotech

Isterian Biotech is a private, preclinical-stage biotech founded in 2018, targeting pathological protein crosslinking as a root cause of fibrosis and aging. The company's core technology involves developing selective inhibitors of transglutaminase 2 (TG2), an enzyme responsible for creating durable crosslinks that resist degradation and drive tissue stiffening and dysfunction. As a subsidiary of Cambrian Bio, Isterian leverages a 'PipeCo' model and over 35 years of collective TG2 research expertise to advance its lead program for idiopathic pulmonary fibrosis (IPF) via inhaled administration. The company operates pre-revenue and aims to address a significant unmet need in a fatal disease with limited treatment options.

Platform focused on developing selective small molecule inhibitors of transglutaminase 2 (TG2) to remove pathological protein crosslinks that accumulate in aged and fibrotic tissues.

The IPF treatment market is served by two approved anti-fibrotic drugs (pirfenidone, nintedanib) that slow decline but do not reverse disease. Isterian's approach of targeting pathological crosslinks for reversal is mechanistically distinct and, if successful, would face competition from other companies developing anti-fibrotics, potentially including other TG2 inhibitors in earlier research stages.